The £7.5 million Longitude Prize on ALS incentivises the use of AI-based approaches to transform drug discovery for amyotrophic lateral sclerosis (ALS).
The five-year Prize will see global multidisciplinary teams compete in a three-phased programme to identify, prioritise and validate high-potential drug targets for ALS, the most common form of motor neurone disease (MND). To drive discovery, the Prize has brought together a range of ALS datasets, working with data holders worldwide, and participants will be provided with access to these data, funding, compute, technical expertise and a range of additional support and partnership opportunities.
Learn more about the Prize “Never before have we had the power to unlock the complexity of MND, and in particular ALS, and accelerate along the road to long-term treatments, and, I hope one day, a cure. The Longitude Prize on ALS makes this possible, convening the largest data set of ALS patient data of its kind ever made available and rewarding researchers to use AI to identify the most promising drug targets.”
We are looking for the brightest minds to bring AI to the fight against ALS.
The Prize will award applicants from across medical research, biotechnology, computational biology and AI with bold ideas on how to harness the power of AI to identify and validate high-potential therapeutic targets for the discovery of transformative ALS therapeutics.
We are looking for:
- AI experts
- Computational biologists and bioinformaticians
- Neurodegenerative disease researchers and ALS researchers
- Biotechnology, techbio and pharmaceutical companies
- Data scientists and engineers
- Clinical experts and medical researchers.
